StreetAlpha.app
Home › Stocks › GOSS

Gossamer Bio, Inc. (GOSS)

$11.21
▲ +2.09%
LAST CLOSE · NOV 17

Gossamer Bio is a San Diego biopharmaceutical company developing seralutinib, an inhaled drug for pulmonary hypertension. It last closed at $11.21 on Nov 17, up 2.09% on the day. The average 12-month price target from 4 analysts is $94.50 (+743.0% from the last close), with a high of $160.00 and a low of $32.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell).

AI Auto Pilots
Is GOSS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$78.4M
+78.0% vs a year ago
Net income
−$125.1M
−159.5% margin
Free cash flow
−$156.0M
−199.0% margin
Operating margin
−140.0%
−$109.8M operating income
Valuation
Market cap
$68.6M
6.1M shares
P/E
–
Price to sales
0.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$51.2M
At Sep 30
Shareholder equity
−$122.8M
Shares outstanding
6.1M
At Nov 7
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $114.7M$114.7MFY2024FY2025: $48.5M$48.5MFY2025

From GOSS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on GOSS in the past 90 days
Average 12-month target
$94.50
▲ 743.0% upside

Based on 4 analysts who set a price target on GOSS in the past 90 days. The average target is $94.50, with a high of $160.00 and a low of $32.00, compared with the last close of $11.21.

Low $32.00Avg $94.50High $160.00
Blue marker: last close $11.21
Highest target$160.00
Average target$94.50
Lowest target$32.00
Latest rating changes
Piper SandlerTarget raised
Nov 11Buy$4 → $96
WedbushMaintained
Nov 11Hold$32
Chardan CapitalMaintained
Oct 15Buy$160
Chardan CapitalInitiated
Oct 13Buy$160
HC Wainwright & Co.Target raised
Sep 21Buy$2 → $90
DateFirmActionRatingPrice target
Nov 11Piper SandlerTarget raisedBuy$4 → $96
Nov 11WedbushMaintainedHold$32
Oct 15Chardan CapitalMaintainedBuy$160
Oct 13Chardan CapitalInitiatedBuy$160
Sep 21HC Wainwright & Co.Target raisedBuy$2 → $90
Loading…

Technical Analysis

GOSS · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 8% above its 20 day and 7% above its 50 day average. It is 163% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 56). The nearest support is the swing low (Jun 10) at $11.20, and the nearest resistance the Pivot R1 at $11.70.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityNormal, 9.4%/day
Key levels
$309.6052 week high+2661.8%
$29.44200 day average+162.6%
$12.15Swing high (Nov 12)+8.4%
$11.99100 day average+7.0%
$11.70Pivot R1+4.4%
$11.21Last close
$11.20Swing low (Jun 10)−0.1%
$10.96Pivot−2.2%
$10.47Pivot S1−6.6%
$10.4450 day average−6.9%
$10.2920 day average−8.2%
$8.2952 week low−26.0%
Indicators
RSI (14)56.36Middle of its rangeNeutral
MACD0.25Above its signal lineBullish
Stochastic70.2Middle of its rangeNeutral
ADX (14)10.5No clear trend
Williams %R-28.1Oversold below −80, overbought above −20Neutral
CCI (20)75.6Oversold below −100, overbought above 100Neutral
Rate of change+20.8%Change over 10 sessionsBullish
ATR (14)$1.05Typical daily range, 9.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for GOSS

What happened before

See how GOSS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GOSS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GOSS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GOSS in the last 90 days.

Loading…

See today’s whale options flow across the market →

GOSS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼72 buying vs 167 selling
  • ▼Held by funds -6178.1 pts
  • ▼Funds holding -96
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding75171−56.1%
In funds' top 1002−100.0%
Held by funds64.7%––
New / increased72 / 027 / 63−20.0%
Reduced / sold out3 / 16444 / 43+92.0%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GOSS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GOSS is in one of them and how their past GOSS trades turned out.

GOSS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GOSS in an article yet. Here's the latest on the wider market.

About Gossamer Bio

Gossamer Bio is a biopharmaceutical company based in San Diego, California. It is developing seralutinib, an investigational inhaled medicine for pulmonary arterial hypertension and for pulmonary hypertension linked to interstitial lung disease. The drug is still in clinical trials and is not yet approved for sale. The company works with Chiesi on development and potential commercialization, and it focuses on people living with pulmonary hypertension.

Headquarters
San Diego, CA